-95%

est. 2Y upside i

HealthcareSeries B

Rank

#4269

Sector

HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Medium

Avail Medsystems was acquired by Mendaera in March 2024, following its cessation of operations due to a failed funding round in late 2023.

Last updated: March 10, 2026

Bull (5%)-50%

Despite ceasing operations, Avail's telepresence technology was acquired by Mendaera for a price that, while significantly below its Series B valuation, provided some recovery for common shareholders after liquidation preferences. This scenario is highly optimistic given the circumstances.

Base (25%)-90%

Avail's acquisition by Mendaera was primarily for its technology assets following a failure to secure further funding and cessation of operations. The acquisition price likely covered investor liquidation preferences but left little to no value for common shareholders.

Bear (70%)-100%

Avail Medsystems ceased operations in late 2023 after failing to close a new funding round, leading to a distressed asset sale to Mendaera. The acquisition price was insufficient to cover the $127M in investor liquidation preferences, resulting in a complete wipeout for common equity holders.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Avail raised $127M in total funding. Assuming a peak Series B post-money valuation of $400M, the investor take ratio was 31.75%, indicating substantial liquidation preferences ahead of common shareholders.

Dilution Risk

high

Prior to its acquisition, Avail's failure to secure additional funding and subsequent cessation of operations suggest significant dilution risk for common shareholders in any potential future rounds, which ultimately materialized as a distressed sale.

Secondary Liquidity

none

As a private company that was acquired in a distressed sale, there was no active secondary market for Avail's equity.

Questions to Ask at the Interview

Strategic questions based on Avail's data — designed to show you've done your homework.

  • 1

    “Given Avail's acquisition by Mendaera, how is the integration of Avail's telepresence technology progressing, and what are the key milestones for its contribution to Mendaera's overall product roadmap over the next 12-24 months?”

  • 2

    “Avail previously faced challenges in securing further funding and ceased operations. What lessons have been learned from Avail's prior business model and market approach, and how is Mendaera mitigating similar risks for the combined entity?”

  • 3

    “Considering the acquisition of Avail's assets, what is Mendaera's long-term vision for liquidity for employees, and how does the equity package for new hires reflect the combined company's current valuation and growth trajectory?”

Community

Valuation Sentiment

Our model estimates -95% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.